hgh frag 176-191

HGH fragment 176-191. sold as 'fat loss without growth.' the AOD9604 trial that tested this idea failed.

tier C · growth hormone · 176-191 AOD-9604 parent

verdict

HGH fragment 176-191. sold as 'fat loss without growth.' the AOD9604 trial that tested exactly that idea failed in phase 2b.

if you're asking whether HGH-Frag actually causes meaningful fat loss in humans — the most rigorous evidence we have on this compound class is AOD9604's phase 2b failure. and AOD9604 is the modified version with better stability. the unmodified fragment has even less human data. community reports are split roughly 50/50 between 'works' and 'does nothing,' which is the response distribution of a compound not reliably doing what it claims.

if you're asking about the 'GH fat-burning without IGF-1' mechanism — the in vitro and animal selectivity concept is real. lipolytic effect without elevating IGF-1 or driving the organ-growth and insulin-resistance effects of full GH. translating that to clinically meaningful human fat loss is where the evidence stops. older work on hyperglycemic effects of C-terminal HGH fragments further complicates the 'clean fat-loss' framing.

on the cut-cycle use case — the side-effect profile in community reports is usually mild, so the risk floor is lower than full HGH. a meaningful subset of users report noticeable fat loss; an equally meaningful subset notice nothing. real research origins, real biology, real clinical disappointment. the marketing strength outruns the data by more than most peptides on the site.

based on published evidence and disclosed clinical practice. not medical advice.

why C-tier

C-tier because the compound has a plausible mechanistic rationale, a genuine research origin at Monash, but the clinical evidence story is not favorable: the modified version (AOD9604) that actually went to Phase 2b failed to produce meaningful weight loss, and the unmodified 176-191 fragment that grey-market vendors sell has even less specific human data. Community reports are split roughly between 'noticeable fat loss during cut cycles' and 'no detectable effect', a bimodal distribution that's hard to reconcile with a consistent pharmacological effect. Not B-tier because the clinical evidence clearly doesn't support the claims. Not D-tier because the compound isn't a marketing invention, it has real research origins and at least partial in vitro and preclinical support for the mechanistic claim.

the core tension

The HGH fragment 176-191 story starts with a genuine research program: Monash University's work in the 1990s-2000s on whether the C-terminal end of growth hormone could be used to target the lipolytic (fat-breakdown) effects of GH without the IGF-1 elevation, insulin resistance, and organ growth effects that accompany full GH therapy. That research produced AOD9604, a modified fragment with an added N-terminal tyrosine. AOD9604 went through Phase 2b obesity trials in Australia and failed to demonstrate clear efficacy for weight loss. The unmodified 176-191 fragment, which is what grey-market vendors typically sell, was the research starting point, not the clinical endpoint, and has even less human trial data than its cousin. The biology is plausible, the cousin failed in trials, and the unmodified fragment's community track record is mixed.

what it is

hgh fragment 176-191 is the 16-residue c-terminal end of human growth hormone, the region associated with lipolytic activity in the parent molecule. identified in the 1990s by frank ng and michael wallis, primarily at monash university. the modified analog aod9604 is the tyrosine-stabilized clinical-development cousin, not the same molecule.

what it does

in vitro and animal studies support a real lipolytic effect: stimulation of triglyceride breakdown in adipose tissue without elevating igf-1 or driving the organ-growth and insulin-resistance effects of full gh. the selectivity concept is mechanistically sound. translating that to clinically meaningful human fat loss is where the evidence stops being supportive.

origin

developed at monash with metabolic pharmaceuticals as an obesity drug candidate. aod9604 cleared phase 1 safety, produced encouraging phase 2a signals, then failed to meet endpoints in phase 2b obesity trials. the program ended. aod9604 found a second life through ingredient-safety positioning, but GRAS-style safety status is not drug approval and not weight-loss efficacy clearance. the unmodified 176-191 fragment that grey-market vendors sell never went through that clinical development at all.

why researchers are interested

the pitch is elegant: gh's fat-burning effect without the side effects. it is cheap, the side effect profile in community reports is usually mild, and a meaningful subset of users report noticeable fat loss during cut cycles. the problem is that the formal human evidence does not back the marketing strength.

does it work

the most rigorous evidence we have on this compound class is aod9604's phase 2b failure, and that is the modified version with better stability. the unmodified fragment has even less human data. community reports are split roughly 50/50 between 'works' and 'does nothing,' which is the response distribution of a compound that is not reliably doing what it claims. older work on hyperglycemic effects of c-terminal hgh fragments complicates the 'clean fat-loss' framing further. real research origins, real biology, real clinical disappointment.

claims vs the data

• C-terminal fragment of human growth hormone — supported — Correct biochemistry. Residues 176-191 of hGH are a real sequence with characterized biology. The unmodified fragment begins with phenylalanine; AOD9604 is the tyrosine-modified cousin.
• stimulates lipolysis in fat cells — partially true — In vitro and animal studies show lipolytic effects, the C-terminal region of GH has been characterized as associated with lipolysis. In human clinical trials of the modified fragment (AOD9604), these in vitro effects did not translate to clinically meaningful weight loss at tested doses.
• reduces body fat in humans without GH side effects — weak — The selectivity claim (lipolysis without IGF-1 elevation) is supported at the mechanistic level, both for full fragment and AOD9604. The clinical claim (meaningful human fat loss at usable doses) is where evidence failed for AOD9604 and is absent for unmodified 176-191 fragment.
• as effective as AOD9604 for fat loss — contradicted — AOD9604 itself failed to demonstrate efficacy in Phase 2b obesity trials. Claims that unmodified 176-191 matches or exceeds AOD9604's effect are claims about matching something that didn't work. The underlying comparative framework doesn't support the conclusion.
• safer than full HGH for fat loss applications — partially true — The selectivity concept is real, fragment doesn't elevate IGF-1 or produce the same organ-growth or insulin-resistance effects as full HGH. So it's mechanistically 'safer' in that narrow sense. But a compound that doesn't work isn't really 'safer than' a compound that does, for the purpose for which people use it.
• increases growth hormone release — contradicted — A fragment of HGH doesn't stimulate endogenous HGH release, it would be a target, not a secretagogue. This claim is mechanistically confused when it appears in marketing, which it sometimes does.
• HGH fragment 176-191 has stronger fat-loss proof than AOD-9604 — overreach — The fragment story mostly borrows from AOD-9604 and older preclinical hGH-fragment work. Direct human efficacy evidence for retail HGH frag is not stronger than the AOD file, and the category remains boxed in by weak effect size.

key facts

• molecular formula: C80H127N23O24S2
• molecular weight: 1859.1 Da as acetate
• amino acids: 16
• half-life: approximately 30 minutes plasma half-life; no validated human dosing schedule
• type: hexadecapeptide (16 amino acids, residues 176-191 of human growth hormone)
• 16 amino acids (vs full HGH's 191)
• Phase 2b level at which AOD9604 failed
• 0 regulatory approvals for weight loss
• ~50% rough split between 'works' and 'does nothing' in community reports

frequently asked questions

What is HGH Frag 176-191?

HGH Frag 176-191 is the C-terminal 16 amino acids of human growth hormone, synthesized as a standalone peptide. It is the unmodified fragment that inspired the development of AOD-9604, a modified analog that underwent clinical obesity trials.

What does HGH Frag 176-191 do?

HGH Frag 176-191 was designed to isolate the lipolytic (fat-mobilizing) activity of growth hormone while avoiding IGF-1 elevation and glucose disruption. Preclinical studies supported the selectivity concept. In human trials of the related AOD-9604, weight loss effects were statistically detectable but clinically modest, not competitive with modern GLP-1 weight-loss drugs.

How is HGH Frag 176-191 typically administered?

Community use is usually sold as short cutting-cycle lore. No FDA-approved or trial-validated dosing schedule exists for unmodified hGH 176-191.

What are the side effects of HGH Frag 176-191?

Side effects are generally mild, occasional injection-site reactions, rare transient headache. Unlike full HGH, the fragment does not meaningfully elevate IGF-1 or cause acromegaly-like effects. Older research on C-terminal HGH fragments noted hyperglycemic effects, which complicates the 'clean fat-loss peptide' framing marketed around the compound.

Is HGH Frag 176-191 FDA approved?

No. The unmodified HGH Frag 176-191 has no FDA approval. The modified AOD-9604 analog has a GRAS safety determination for intended ingredient use, not FDA drug approval and not weight-loss efficacy clearance. The compound falls under WADA Prohibited List S2.

How much does HGH Frag 176-191 cost?

No clinical retail price. On the research-chemical market it is inexpensive, reflecting its small peptide size and simple synthesis.

related peptides

• hgh — S-tier full growth hormone, what fragment users are trying to selectively reproduce
• aod 9604 — D-tier modified fragment cousin that actually went through (and failed) clinical trials
• cjc+ipa blend — A-tier GH-axis stack with stronger community track record

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.